Form 4: Ionis Pharma CEO Trades Shares Under 10b5-1 Plan

Ionis Pharmaceuticals CEO Brett P. Monia executed a series of stock transactions, acquiring and selling common stock under a pre-arranged trading plan.

Summary

• Brett P. Monia, CEO of Ionis Pharmaceuticals, Inc., engaged in multiple stock transactions between June 24 and June 26, 2026.
• These transactions involved the acquisition of common stock at prices ranging from $32.60 to $56.78.
• Simultaneously, Monia sold shares at weighted average prices between $78.00 and $81.00.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on December 8, 2025.
• Following these transactions, Monia's beneficial ownership of common stock changed.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While insider selling can be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns about illegal insider trading, suggesting a planned divestment rather than a reaction to non-public information.

Positives

• The transactions were executed under a Rule 10b5-1 plan, which is designed to comply with insider trading regulations and provides an affirmative defense against allegations of insider trading.
• The CEO acquired additional shares at lower prices, potentially indicating a belief in the company's future value at those price points.

Negatives

• Significant sales of company stock by the CEO could be perceived negatively by the market, potentially signaling a lack of confidence or a need for personal liquidity.
• The sales occurred at prices substantially higher than the acquisition prices, indicating a realized gain for the reporting person.

Risks

• Market perception of insider selling can negatively impact stock price, regardless of the underlying reasons or compliance with trading plans.
• The weighted average sale prices suggest a range of market conditions during the transaction period, which could reflect volatility.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding future financial performance. The transactions are based on a pre-existing trading plan.

Management Comments

• The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), and (4).

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions are common in the pharmaceutical and biotechnology sectors, where executive compensation often includes stock options and grants. The use of Rule 10b5-1 plans is a standard practice for executives to manage their stock holdings while adhering to regulatory requirements.

Stakeholder Impact

• Shareholders: May interpret the CEO's sales as a negative signal, potentially impacting stock price, although the Rule 10b5-1 plan provides a degree of reassurance.
• Employees: May be influenced by the CEO's stock activity, potentially affecting morale or investment decisions.
• Management: The transactions highlight the importance of adhering to corporate governance and insider trading regulations.

Next Steps

• The reporting person may continue to execute transactions under the Rule 10b5-1 plan.
• Ionis Pharmaceuticals, Inc. may be required to provide detailed transaction information upon request from the SEC or shareholders.

Key Dates

Recommendation

The filing details routine stock transactions by the CEO under a pre-established 10b5-1 plan. While insider selling can be a concern, the structured nature of these trades suggests a planned divestment rather than a reaction to adverse non-public information. Without additional context on the company's performance or future prospects, a 'hold' recommendation is appropriate, acknowledging the potential market reaction to insider sales while recognizing the compliance aspect of the transactions.

Keywords

Form 4, SEC Filing, Insider Trading, Stock Transaction, Rule 10b5-1, Ionis Pharmaceuticals, IONS, CEO, Common Stock, Beneficial Ownership